Clinical Collaboration

Selected news for the healthcare topic - Clinical Collaboration, collected since 10/2017. There are 1K items in the archive. This healthcare topic shares news with Merck, Bristol-Myers, Bristol-Myers Squibb, Gilead, Oncology and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/31/2022 Agenus Advances Portfolio with 6 Clinical Collaborations healthtechnologynet.com Agenus Advances Portfolio with 6 Clinical CollaborationsLEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations. These 6 collaborations span a range of ...
5/31/2022 Agenus Advances Portfolio with 6 Clinical Collaborations Globe Newswire LEXINGTON, Mass., Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations. These 6 collaborations span a range of Agenus’ clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma Business Wire ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma buffalonews.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma | Insider Tracking insidertracking.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD. “We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma neuro-central.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma | Business | The Daily News galvnews.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 NovoCure Ltd. (NVCR) Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma researchpool.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma inyoregister.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/26/2022 Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma smdailypress.com ... to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) for the treatment of patients with newly diagnosed glioblastoma (GBM). This is the second clinical collaboration between Novocure and MSD.“We are excited to collaborate again with global oncology leader, MSD, in the pursuit of extending survival in some of the most aggressive forms of cancer,” said William Doyle ...
5/24/2022 DrFirst Recognizes Healthcare Organizations for Excellence in Using Technology to Improve Care Collaboration, Interoperability, Efficiency, and Patient Outcomes PR Newswire ... Health technology pioneer DrFirst today announced the winners of its Healthiverse Heroes Award , which honors organizations for using technology in innovative ways to break through the information silos that get in the way of clinical collaboration and patient care."The resilience, dedication, and grit exhibited by healthcare organizations throughout the COVID-19 pandemic are an inspiration to all of us," said G. Cameron Deemer , president of DrFirst. "It is our ...
5/24/2022 AZZLY®, Inc. Earns Honorable Mention in DrFirst's 2022 Healthiverse Heroes Awards PRWeb ... Fla.Health technology pioneer DrFirst® today announced the winners of its second annual Healthiverse Heroes Awards, honoring healthcare providers and organizations that are breaking through information silos that stand in the way of clinical collaboration and patient care.AZZLY®, Inc. was awarded an honorable mention in the Technology Partners category of the 2022 Healthiverse Heroes Awards. AZZLY was recognized for its innovative use of technology to increase efficiency ...
5/24/2022 Mobile Heartbeat Announces Integration Partnership to Decrease Clinician Reaction Time Yahoo News Clinical Collaboration Provider Integrates with Stryker’s iBed Wireless System to Decrease Clinician Reaction Time During Bed EventsWALTHAM, Mass., May 24, 2022 --( BUSINESS WIRE )--Leading clinical collaboration software provider Mobile Heartbeat today announced an integration partnership with medical technology company Stryker Corporation. The integration primarily facilitates alerts to Mobile Heartbeat’s unified collaboration platform, MH-CURE, from Stryker’s iBed Wireless system .Through the integration, which leverages Mobile Heartbeat ...
5/16/2022 Athenex (ATNX) Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC) researchpool.com Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)BUFFALO, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside ...
5/16/2022 Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC), Business News - AsiaOne asiaone.com Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC) GlobeNewswire May 16, 2022 BUFFALO, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a clinical trial collaboration and supply agreement with Merck ...
4/1/2022 4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 Business Wire ... corporate objectives for 2022.“2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger with Longevity Acquisition Corporation which led to 4D pharma being ...
4/1/2022 4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022 | Business Wire Business Wire ... corporate objectives for 2022.“2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger with Longevity Acquisition Corporation which led to 4D pharma being ...
3/28/2022 Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress Yahoo News ... with recurrent LGSOC and in patients with recurrent KRAS G12V-mutant NSCLC as part of its RAMP (Raf And Mek Program) clinical trials, RAMP 201 and RAMP 202, respectively. Verastem Oncology has also established clinical collaboration s with Amgen and Mirati to evaluate LUMAKRAS‚Ñ¢ (sotorasib) and adagrasib in combination with VS-6766 in KRAS G12C-mutant NSCLC as part of the RAMP 203 and RAMP 204 trials, respectively.About Verastem ...
3/22/2022 Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer dishysammy.com ... March Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has established a global clinical collaboration with Bristol Myers Squibb to evaluate the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 developed by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the ...
3/22/2022 Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer prnasia.com ... 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has established a global clinical collaboration with Bristol Myers Squibb to evaluate the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 developed by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy, for the treatment ...